A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Public ClinicalTrials.gov record NCT07799532. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291. The main questions it aims to answer are: * Does NVG-291 improve hand function and daily activities? * What side effects do participants have when taking NVG-291? Researchers will compare NVG-291 to a placebo (a look-alike substance that does not contain NVG-291) to see if NVG-291 improves function in adults with chronic cervical motor-incomplete spinal cord injury. Participants will: * Take NVG-291 or a placebo by injection under the skin (subcutaneous) once daily for 12 weeks. * Attend clinic visits for checkups and safety tests. * Complete tests and questionnaires about hand function, walking, daily activities, and quality of life. * Take part in an interview about changes in their condition, within 14 days after the Week 12 visit.
Study identification
- NCT ID
- NCT07799532
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2026 (Actual)
- Primary completion
- Jul 2027 (Estimated)
- Completion
- Dec 14, 2027 (Estimated)
- Last update posted
- Nov 3, 2026
2026 – 2027
United States locations
- U.S. sites
- 21
- U.S. states
- 19
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NervGen NVG-291-301 Site#104 | Birmingham | Alabama | 35294 | Not yet recruiting |
| NervGen NVG-291-301 Site# 118 | Pheonix | Arizona | 85013 | Not yet recruiting |
| NervGen NVG-291-301 Site#109 | Downey | California | 90242 | Not yet recruiting |
| NervGen NVG-291-301 Site#106 | Englewood | Colorado | 80113 | Not yet recruiting |
| New England Institue for Clinical Research | Stamford | Connecticut | 06905 | Recruiting |
| NervGen NVG-291-301 Site#112 | Washington D.C. | District of Columbia | 20010 | Not yet recruiting |
| NervGen NVG-291-301 Site#107 | Miami | Florida | 33136 | Not yet recruiting |
| NervGen NVG-291-301 Site#101 | Atlanta | Georgia | 30309 | Not yet recruiting |
| International Neurorehabilitation Institute | Lutherville | Maryland | 21093 | Recruiting |
| NervGen NVG-291-301 Site # 121 | Boston | Massachusetts | 02138 | Not yet recruiting |
| NervGen NVG-291-301 Site#111 | Rochester | Minnesota | 55905 | Not yet recruiting |
| NervGen NVG-291-301 Site#115 | Camden | New Jersey | 08103 | Not yet recruiting |
| NervGen NVG-291-301 Site#117 | Paramus | New Jersey | 07652 | Not yet recruiting |
| NervGen NVG-291-301 Site#114 | West Orange | New Jersey | 07052 | Not yet recruiting |
| NervGen NVG-291-301 Site#108 | Charlotte | North Carolina | 28203 | Not yet recruiting |
| NervGen NVG-291-301 Site# 119 | Cleveland | Ohio | 44111 | Not yet recruiting |
| NervGen NVG-291-301 Site#116 | Philadelphia | Pennsylvania | 19146 | Not yet recruiting |
| NervGen NVG-291-301 Site#113 | Charleston | South Carolina | 29425 | Not yet recruiting |
| NervGen NVG-291-301 Site#110 | Houston | Texas | 77030 | Not yet recruiting |
| NervGen NVG-291-301 Site# 120 | Richmond | Virginia | 23298 | Not yet recruiting |
| NervGen NVG-291-301 Site#102 | Milwaukee | Wisconsin | 53226 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07799532, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2026 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07799532 live on ClinicalTrials.gov.